Kymera Investor Presentation Deck

Clinical and Near-Term Clinical Pipeline of Novel Protein Degraders Immunology Programs IRAK4* Transcription Factor IL4/13 Pathway Scaffolding Kinase STAT3 Oncology Programs STAT3 MDM2 Potential Indication(s) HS, AD, RA, Other AD, Asthma, COPD, EoE, PN Psoriasis, IBD, Lupus, Other Autoimmune & Fibrotic Diseases Potential Indication(s) PTCL, LGL-L, CTCL, Solid Tumors Liquid & Solid Tumors Preclinical Phase 1 KYMERA ©2023 KYMERA THERAPEUTICS, INC. KT-474 - Hidradenitis Suppurativa KT-474 - Atopic Dermatitis 00 Preclinical KT-333 KT-253 Phase 2 Phase 1 Phase 2 *KT-474 partnered with Sanofi, with Kymera option to participate equally in the development and commercialization in the United States. Phase 3 Phase 3 Upcoming Milestones Topline HS Data 1H 2025 Topline AD Data 1H 2025 R&D Day January 2024 R&D Day January 2024 R&D Day January 2024 Upcoming Milestones Clinical Activity: ASH 2023 Clinical Activity: 2024 Rights with sanofi KYMERA KYMERA KYMERA Rights KYMERA KYMERA PAGE 6

View entire presentation